Holen Sie sich die Stockscreener-App
4.255
14.39%
-0.715
Schlusskurs vom Vortag:
$4.97
Offen:
$4.36
24-Stunden-Volumen:
1.60M
Relative Volume:
1.42
Marktkapitalisierung:
$338.89M
Einnahmen:
$129.42M
Nettoeinkommen (Verlust:
$17.38M
KGV:
20.83
EPS:
0.2043
Netto-Cashflow:
$13.15M
1W Leistung:
-10.04%
1M Leistung:
-4.81%
6M Leistung:
-37.79%
1J Leistung:
-49.64%
1-Tages-Spanne:
$4.038
$4.3876
1-Wochen-Bereich:
$4.038
$5.1214
52-Wochen-Spanne:
$4.038
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Firmenname
Niagen Bioscience Inc
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
4.255 | 395.83M | 129.42M | 17.38M | 13.15M | 0.2043 |
VRTX
Vertex Pharmaceuticals Inc
|
426.46 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
709.05 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.49 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.44 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.71 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
| 2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results - BioSpace
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED) - Benzinga
Niagen Bioscience reaffirms 10%-15% 2026 growth outlook while increasing marketing spend expectations - MSN
Niagen Bioscience Earnings Call Highlights Growth Push - TipRanks
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition - Investing.com
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Niagen Bioscience Reports Q1 Results, Updates 2026 Outlook - TipRanks
Niagen (NAGE) Q1 2026 Earnings Call Transcript - AOL.com
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce - Investing.com
Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance - ChartMill
Niagen Bioscience: Q1 Earnings Snapshot - marketscreener.com
[8-K] Niagen Bioscience, Inc. Reports Material Event - Stock Titan
Segment sale lifts Niagen Bioscience (Nasdaq: NAGE) Q1 2026 profit - Stock Titan
Niagen Bioscience Is Maintained at Buy by Canaccord Genuity - Moomoo
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Niagen Bioscience Inc expected to post earnings of 8 cents a shareEarnings Preview - TradingView
Niagen Bioscience (NAGE) Launches Telehealth Platform for Home D - GuruFocus
Niagen Bioscience launches telehealth platform with at-home kit - Investing.com UK
Niagen Bioscience Enters Telehealth With At-Home NAD+ Precursor Injection Kits - Athletech News
Niagen Bioscience launches telehealth platform with at-home kit By Investing.com - Investing.com India
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering - 巴士的報
NAGE Technical Analysis | Trend, Signals & Chart Patterns | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience (NAGE) outlines 2026 director elections, auditor ratification and executive pay vote - Stock Titan
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus - BioSpace
Insider Decision Unfolding At Niagen Bioscience: Robert Fried Exercises Options, Resulting In $46K - Benzinga
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™ - Yahoo Finance
Insider Decision Unfolding At Niagen Bioscience: CEO Robert Fried Exercises Options(CORRECTED) - Benzinga
Notable Insider Move: Robert Fried Takes Part In Options Exercise At Niagen Bioscience, Resulting In $45K - Benzinga
Niagen Bioscience (NAGE) CEO adds 20,000 shares via option exercise - Stock Titan
Wall Street Zen Downgrades Niagen Bioscience (NASDAQ:NAGE) to Hold - MarketBeat
Niagen Bioscience Secures USP Monograph and Extends NR Patent Protection - HarianBasis.co
NAGE (Niagen Bioscience Inc.) reports solid Q4 2025 EPS beat and nearly 30 percent year over year revenue growth, stock rises modestly.Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 - BioSpace
Niagen Bioscience (NAGE) Well-Positioned With Recent Dietary Supplement Ingredient Monograph - Yahoo Finance
Niagen Bioscience (NAGE) price target decreased by 13.92% to 13.87 - MSN
Is Niagen Bioscience (NAGE) stock losing bullish momentum | Q4 2025: EPS Exceeds ExpectationsCommunity Buy Signals - Cổng thông tin điện tử Tỉnh Sơn La
How The Niagen Bioscience (NAGE) Story Is Shifting With New Q4 Models And Injectables - Yahoo Finance
Niagen Bioscience Stock Short Interest Report | NASDAQ:NAGE - Benzinga
Is Niagen Bioscience (NAGE) stock holding under pressure (Near Lows) 2026-04-20Social Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unveiling a Potential 187.53% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration - Sahm
NAGE Stock Price, Quote & Chart | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy (NASDAQ:NAGE) - Seeking Alpha
Niagen: High-Quality Growth At A Fair Price (NASDAQ:NAGE) - Seeking Alpha
Value Recap: Will Niagen Bioscience Inc stock go up in YEAR2026 Setups & Free High Return Stock Watch Alerts - baoquankhu1.vn
Q3 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Finanzdaten der Niagen Bioscience Inc-Aktie (NAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Niagen Bioscience Inc-Aktie (NAGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.81 |
4,465 |
30,406 |
7,372 |
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.85 |
2,220 |
15,210 |
2,220 |
5.78%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):